JD Health Reports H1 Net Profit of 3.4 Billion Yuan, Up 32% YoY
Nashnova编辑部
JD Health reported first-half net profit of RMB 3.437 billion, up 32.4% year-on-year — profit grew twice as fast as revenue, signaling the online healthcare platform is shifting from selling more to earning more.
How much did it earn, and where did growth come from?
First-half revenue reached RMB 40.888 billion, up 15.9% year-on-year; net profit hit RMB 3.437 billion, up 32.4%.
This means → for every extra yuan of sales, a larger share dropped to the bottom line than a year ago.
Non-IFRS operating margin rose from 7.0% to 8.5%; basic earnings per share came in at RMB 1.08.
Why is the margin still improving?
Non-IFRS operating profit reached RMB 3.483 billion, up 40.3% — the fastest growth rate among all key metrics.
In plain terms = the company squeezed more out of cost control and operations, not just higher sales volume.
This reflects a business-model shift from chasing scale to chasing quality — and investor focus will follow.
What policy tailwinds are behind this?
The State Council's 15th Five-Year Plan for expanding consumption explicitly backs health spending and new health-management services.
The National Health Commission issued guidelines supporting medical vertical large-language models — AI models trained specifically for healthcare — and medical intelligent agents.
This means → policy opened two doors at once, consumer demand and technology adoption, giving JD Health's AI-healthcare push official backing.
What should investors watch in H2?
The company said it will keep deploying AI across healthcare consumption scenarios and expand online-to-offline services.
The market's two key checkpoints: can revenue growth hold, and is the margin expansion sustainable?
In plain terms = the first-half scorecard looks solid, but H2 is the real test of whether this "earn more, spend less" model truly sticks.
Content is for reference only, not financial advice.